Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Causes & Control
Published in: Cancer Causes & Control 7/2010

01-07-2010 | Original paper

Racial differences in PSA screening interval and stage at diagnosis

Authors: William R. Carpenter, Daniel L. Howard, Yhenneko J. Taylor, Louie E. Ross, Sara E. Wobker, Paul A. Godley

Published in: Cancer Causes & Control | Issue 7/2010

Login to get access

Abstract

Objectives

This study examined PSA screening interval of black and white men aged 65 or older and its association with prostate cancer stage at diagnosis.

Methods

SEER-Medicare data were examined for 18,067 black and white men diagnosed with prostate cancer between 1994 and 2002. Logistic regression was used to assess the association between race, PSA screening interval, and stage at diagnosis. Analysis also controlled for age, marital status, comorbidity, diagnosis year, geographic region, income, and receipt of surgery.

Results

Compared to whites, blacks diagnosed with prostate cancer were more likely to have had a longer PSA screening interval prior to diagnosis, including a greater likelihood of no pre-diagnosis use of PSA screening. Controlling for PSA screening interval was associated with a reduction in blacks’ relative odds of being diagnosed with advanced (stage III or IV) prostate cancer, to a point that the stage at diagnosis was not statistically different from that of whites (OR=1.12, 95% CI=0.98–1.29). Longer intra-PSA intervals were systematically associated with greater odds of diagnosis with advanced disease.

Conclusions

More frequent or systematic PSA screening may be a pathway to reducing racial differences in prostate cancer stage at diagnosis, and, by extension, mortality.
Literature
1.
American Cancer Society (2009) Cancer facts & figures 2009. American Cancer Society, Atlanta
2.
American Cancer Society (2009) Cancer facts and figures for African Americans, 2009-10. American Cancer Society, Atlanta
3.
Institute of Medicine (2003) Unequal treatment: confronting racial and ethnic disparities in healthcare. National Academies Press, Washington DC
4.
Institute of Medicine (1999) The unequal burden of cancer: as assessment of NIH research and programs for ethnic minorities and the medically underserved. National Academies Press, Washington DC
5.
Bach PB, Cramer LD, Warren JL, Begg CB (1999) Racial differences in the treatment of early-stage lung cancer. N Engl J Med 341(16):1198–1205CrossRefPubMed
6.
Field TS, Buist DS, Doubeni C et al. (2005) Disparities and survival among breast cancer patients. J Natl Cancer Inst Monogr (35):88–95
7.
Harlan L, Brawley O, Pommerenke F, Wali P, Kramer B (1995) Geographic, age, and racial variation in the treatment of local/regional carcinoma of the prostate. J Clin Oncol 13(1):93–100PubMed
8.
Gilligan T, Wang PS, Levin R, Kantoff PW, Avorn J (2004) Racial differences in screening for prostate cancer in the elderly. Arch Intern Med 164(17):1858–1864CrossRefPubMed
9.
Giovannucci E, Stampfer MJ, Krithivas K et al (1997) The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc Natl Acad Sci USA 94(7):3320–3323CrossRefPubMed
10.
Hayes RB, Ziegler RG, Gridley G et al (1999) Dietary factors and risks for prostate cancer among blacks and whites in the United States. Cancer Epidemiol Biomarkers Prev 8(1):25–34PubMed
11.
Lichtenstein P, Holm NV, Verkasalo PK et al (2000) Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 343(2):78–85CrossRefPubMed
12.
Moul JW, Sesterhenn IA, Connelly RR et al (1995) Prostate-specific antigen values at the time of prostate cancer diagnosis in African-American men. JAMA 274(16):1277–1281CrossRefPubMed
13.
Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO (1997) Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 277(6):467–471CrossRefPubMed
14.
Jonsson E, Sigbjarnarson HP, Tomasson J et al (2006) Adenocarcinoma of the prostate in Iceland: a population-based study of stage, Gleason grade, treatment and long-term survival in males diagnosed between 1983 and 1987. Scand J Urol Nephrol 40(4):265–271CrossRefPubMed
15.
Tabar L, Fagerberg CJ, Gad A et al (1985) Reduction in mortality from breast cancer after mass screening with mammography. Randomised trial from the breast cancer screening working group of the Swedish national board of health and welfare. Lancet 1(8433):829–832CrossRefPubMed
16.
Mandel JS, Bond JH, Church TR et al (1993) Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med 328(19):1365–1371CrossRefPubMed
17.
Laara E, Day NE, Hakama M (1987) Trends in mortality from cervical cancer in the Nordic countries: association with organised screening programmes. Lancet 1(8544):1247–1249PubMed
18.
Amling CL (2006) Prostate-specific antigen and detection of prostate cancer: what have we learned and what should we recommend for screening? Curr Treat Options Oncol 7(5):337–345CrossRefPubMed
19.
Agalliu I, Weiss NS, Lin DW, Stanford JL (2007) Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men. Cancer Causes Control 18(9):931–937CrossRefPubMed
20.
Weinmann S, Richert-Boe K, Glass AG, Weiss NS (2004) Prostate cancer screening and mortality: a case-control study (United States). Cancer Causes Control 15(2):133–138CrossRefPubMed
21.
Oberaigner W, Horninger W, Klocker H, Schonitzer D, Stuhlinger W, Bartsch G (2006) Reduction of prostate cancer mortality in Tyrol, Austria, after introduction of prostate-specific antigen testing. Am J Epidemiol 164(4):376–384CrossRefPubMed
22.
Andriole GL, Crawford ED, Grubb RL III et al (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360(13):1310–1319CrossRefPubMed
23.
Schroder FH, Hugosson J, Roobol MJ et al (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360(13):1320–1328CrossRefPubMed
24.
Smith DS, Catalona WJ, Herschman JD (1996) Longitudinal screening for prostate cancer with prostate-specific antigen. JAMA 276(16):1309–1315CrossRefPubMed
25.
Gilliland FD, Hunt WC, Key CR (1996) Improving survival for patients with prostate cancer diagnosed in the prostate-specific antigen era. Urology 48(1):67–71CrossRefPubMed
26.
Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG (2004) Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100(7):1397–1405CrossRefPubMed
27.
Ung JO, Richie JP, Chen MH, Renshaw AA, D’Amico AV (2002) Evolution of the presentation and pathologic and biochemical outcomes after radical prostatectomy for patients with clinically localized prostate cancer diagnosed during the PSA era. Urology 60(3):458–463CrossRefPubMed
28.
Virnig BA, Baxter NN, Habermann EB, Feldman RD, Bradley CJ (2009) A matter of race: early-versus late-stage cancer diagnosis. Health Aff (Millwood) 28(1):160–168CrossRef
29.
Hugosson J, Aus G, Bergdahl S et al (2003) Population-based screening for prostate cancer by measuring free and total serum prostate-specific antigen in Sweden. BJU Int 92(Suppl 2):39–43CrossRefPubMed
30.
Kundu SD, Grubb RL, Roehl KA, Antenor JA, Han M, Catalona WJ (2005) Delays in cancer detection using 2 and 4-year screening intervals for prostate cancer screening with initial prostate specific antigen less than 2 ng/ml. J Urol 173(4):1116–1120CrossRefPubMed
31.
Warren JL, Klabunde CN, Schrag D et al (2002) Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care 40:3–18
32.
Fritz A, Ries L (eds) (1998) The SEER program code manual, 3rd edn. National Cancer Institute, Bethesda, MD
33.
Yao SL, Lu-Yao G (2001) Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer. J Urol 166:861–865CrossRefPubMed
34.
Klabunde CN, Potosky AL, Legler JM, Warren JL (2000) Development of a comorbidity index using physician claims data. J.Clin Epidemiol 53:1258–1267CrossRefPubMed
35.
Barry MJ (2009) Screening for prostate cancer—the controversy that refuses to die. NEJM 360(13):1351–1354CrossRefPubMed
36.
Zoorob R, Anderson R, Cefalu C, Sidani M (2001) Cancer screening guidelines. Am Fam Physician 63(6):1101–1112PubMed
37.
Carpenter WR, Godley PA, Finnegan T, Talcott JA, Clark JA, Mishel M, Schroeder JC, Bensen JT, Su JL, Fontham ETH, Mohler JL (2009) Racial differences in the roles of trust, regular source of patient care, and screening and treatment utilization among individuals with prostate cancer. Cancer 155(21):5048–5059CrossRef
38.
Talcott JA, Spain P, Clark JA, Carpenter WR, Do YK, Hamilton RJ, Galanko JA, Jackman A, Godley PA (2007) Hidden barriers between knowledge and behavior: the North Carolina prostate cancer screening and treatment experience. Cancer 109(8):1599–1606CrossRefPubMed
39.
Albain KS, Unger JM, Crowley JJ, Coltman CA Jr, Hershman DL (2009) Racial disparities in cancer survival among randomized clinical trials patients of the Southwest oncology group. JNCI 101(14):984–992PubMed
40.
Lacher DA, Thompson TD, Hughes JP, Saraiya M (2006) Total, free, and percent free prostate-specific antigen levels among US men, 2001–04. Adv Data 379:1–12PubMed
41.
Efstathiou JA, Chen MH, Catalona WJ et al (2006) Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality. Urology 68(2):342–347CrossRefPubMed
42.
Ulmert D, Cronin AM, Bjork T et al (2008) Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med 6:6CrossRefPubMed
Metadata
Title
Racial differences in PSA screening interval and stage at diagnosis
Authors
William R. Carpenter
Daniel L. Howard
Yhenneko J. Taylor
Louie E. Ross
Sara E. Wobker
Paul A. Godley
Publication date
01-07-2010
Publisher
Springer Netherlands
Published in
Cancer Causes & Control / Issue 7/2010
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-010-9535-4

Other articles of this Issue 7/2010

Cancer Causes & Control 7/2010 Go to the issue

Original paper

Intake of fiber and nuts during adolescence and incidence of proliferative benign breast disease

Original paper

Meeting the cervical cancer screening needs of underserved women: The National Breast and Cervical Cancer Early Detection Program, 2004–2006

Brief report

A case–control study of tobacco use and other non-occupational risk factors for lymphoma subtypes defined by t(14; 18) translocations and bcl-2 expression

Original paper

Primary peritoneal and ovarian cancers: an epidemiological comparative analysis

Review article

Pregnancy characteristics and maternal breast cancer risk: a review of the epidemiologic literature

Original paper

A prospective study of one-carbon metabolism biomarkers and risk of renal cell carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits